Targeting  ||| S:0 E:10 ||| VBG
innate  ||| S:10 E:17 ||| JJ
immune  ||| S:17 E:24 ||| JJ
pathways  ||| S:24 E:33 ||| NN
in  ||| S:33 E:36 ||| IN
cancer  ||| S:36 E:43 ||| NN
immunotherapy ||| S:43 E:56 ||| NNS
:  ||| S:56 E:58 ||| :
state  ||| S:58 E:64 ||| NN
of  ||| S:64 E:67 ||| IN
the  ||| S:67 E:71 ||| DT
art  ||| S:71 E:75 ||| NN
Complement-based  ||| S:75 E:92 ||| JJ
cancer  ||| S:92 E:99 ||| NN
immunotherapy  ||| S:99 E:113 ||| NN
is  ||| S:113 E:116 ||| VBZ
gaining  ||| S:116 E:124 ||| VBG
momentum  ||| S:124 E:133 ||| NN
in  ||| S:133 E:136 ||| IN
recent  ||| S:136 E:143 ||| JJ
years  ||| S:143 E:149 ||| NNS
due  ||| S:149 E:153 ||| JJ
to  ||| S:153 E:156 ||| TO
the  ||| S:156 E:160 ||| DT
growing  ||| S:160 E:168 ||| VBG
number  ||| S:168 E:175 ||| NN
of  ||| S:175 E:178 ||| IN
therapeutic  ||| S:178 E:190 ||| JJ
anti-tumor  ||| S:190 E:201 ||| JJ
antibodies  ||| S:201 E:212 ||| NNS
that  ||| S:212 E:217 ||| WDT
are  ||| S:217 E:221 ||| VBP
receiving  ||| S:221 E:231 ||| VBG
approval  ||| S:231 E:240 ||| NN
for  ||| S:240 E:244 ||| IN
clinical  ||| S:244 E:253 ||| JJ
trials  ||| S:253 E:260 ||| NNS
and  ||| S:260 E:264 ||| CC
are  ||| S:264 E:268 ||| VBP
currently  ||| S:268 E:278 ||| RB
used  ||| S:278 E:283 ||| VBN
in  ||| S:283 E:286 ||| IN
clinical  ||| S:286 E:295 ||| JJ
cancer  ||| S:295 E:302 ||| NN
care ||| S:302 E:306 ||| NN
.  ||| S:306 E:308 ||| .
Even  ||| S:308 E:313 ||| RB
though  ||| S:313 E:320 ||| IN
some  ||| S:320 E:325 ||| DT
anti-tumor  ||| S:325 E:336 ||| JJ
antibodies  ||| S:336 E:347 ||| NNS
have  ||| S:347 E:352 ||| VBP
shown  ||| S:352 E:358 ||| VBN
moderate  ||| S:358 E:367 ||| JJ
therapeutic  ||| S:367 E:379 ||| JJ
efficacy ||| S:379 E:387 ||| NN
,  ||| S:387 E:389 ||| ,
most  ||| S:389 E:394 ||| JJS
of  ||| S:394 E:397 ||| IN
them  ||| S:397 E:402 ||| PRP
still  ||| S:402 E:408 ||| RB
lag  ||| S:408 E:412 ||| VBP
behind ||| S:412 E:418 ||| RB
,  ||| S:418 E:420 ||| ,
having  ||| S:420 E:427 ||| VBG
failed  ||| S:427 E:434 ||| VBN
to  ||| S:434 E:437 ||| TO
produce  ||| S:437 E:445 ||| VB
adequately  ||| S:445 E:456 ||| RB
effective  ||| S:456 E:466 ||| JJ
responses ||| S:466 E:475 ||| NNS
.  ||| S:475 E:477 ||| .
The  ||| S:477 E:481 ||| DT
urging  ||| S:481 E:488 ||| VBG
need  ||| S:488 E:493 ||| NN
for  ||| S:493 E:497 ||| IN
a  ||| S:497 E:499 ||| DT
therapeutic  ||| S:499 E:511 ||| JJ
platform  ||| S:511 E:520 ||| NN
that  ||| S:520 E:525 ||| WDT
will  ||| S:525 E:530 ||| MD
enhance  ||| S:530 E:538 ||| VB
both  ||| S:538 E:543 ||| PDT
the  ||| S:543 E:547 ||| DT
humoral  ||| S:547 E:555 ||| NN
and  ||| S:555 E:559 ||| CC
cellular  ||| S:559 E:568 ||| JJ
effects  ||| S:568 E:576 ||| NNS
of  ||| S:576 E:579 ||| IN
antibody  ||| S:579 E:588 ||| NN
treatment  ||| S:588 E:598 ||| NN
prompts  ||| S:598 E:606 ||| VBZ
the  ||| S:606 E:610 ||| DT
design  ||| S:610 E:617 ||| NN
of  ||| S:617 E:620 ||| IN
more  ||| S:620 E:625 ||| RBR
effective  ||| S:625 E:635 ||| JJ
combinatorial  ||| S:635 E:649 ||| JJ
therapeutics  ||| S:649 E:662 ||| NN
for  ||| S:662 E:666 ||| IN
enhancing  ||| S:666 E:676 ||| VBG
complement-mediated  ||| S:676 E:696 ||| JJ
tumor  ||| S:696 E:702 ||| NN
cytotoxicity  ||| S:702 E:715 ||| NN
in  ||| S:715 E:718 ||| IN
cancer  ||| S:718 E:725 ||| NN
patients ||| S:725 E:733 ||| NNS
.  ||| S:733 E:735 ||| .
Cancer  ||| S:735 E:742 ||| NN
cells  ||| S:742 E:748 ||| NNS
express  ||| S:748 E:756 ||| VBP
or  ||| S:756 E:759 ||| CC
sequester  ||| S:759 E:769 ||| JJ
host  ||| S:769 E:774 ||| NN
membrane-bound  ||| S:774 E:789 ||| NN
and  ||| S:789 E:793 ||| CC
fluid-phase  ||| S:793 E:805 ||| JJ
complement  ||| S:805 E:816 ||| JJ
regulators  ||| S:816 E:827 ||| NNS
in  ||| S:827 E:830 ||| IN
order  ||| S:830 E:836 ||| NN
to  ||| S:836 E:839 ||| TO
evade  ||| S:839 E:845 ||| VB
complement  ||| S:845 E:856 ||| JJ
attack  ||| S:856 E:863 ||| NN
and  ||| S:863 E:867 ||| CC
establish  ||| S:867 E:877 ||| VB
an  ||| S:877 E:880 ||| DT
immunosuppressive  ||| S:880 E:898 ||| JJ
microenvironment  ||| S:898 E:915 ||| NN
for  ||| S:915 E:919 ||| IN
tumor  ||| S:919 E:925 ||| NN
growth ||| S:925 E:931 ||| NN
.  ||| S:931 E:933 ||| .
Moreover ||| S:933 E:941 ||| RB
,  ||| S:941 E:943 ||| ,
membrane  ||| S:943 E:952 ||| JJ
complement  ||| S:952 E:963 ||| JJ
regulators  ||| S:963 E:974 ||| NNS
appear  ||| S:974 E:981 ||| VBP
to  ||| S:981 E:984 ||| TO
modulate  ||| S:984 E:993 ||| VB
several  ||| S:993 E:1001 ||| JJ
aspects  ||| S:1001 E:1009 ||| NNS
of  ||| S:1009 E:1012 ||| IN
T-cell  ||| S:1012 E:1019 ||| JJ
immunity  ||| S:1019 E:1028 ||| NN
that  ||| S:1028 E:1033 ||| WDT
are  ||| S:1033 E:1037 ||| VBP
relevant  ||| S:1037 E:1046 ||| JJ
to  ||| S:1046 E:1049 ||| TO
the  ||| S:1049 E:1053 ||| DT
anti-tumor ||| S:1053 E:1063 ||| JJ
,  ||| S:1063 E:1065 ||| ,
adaptive  ||| S:1065 E:1074 ||| JJ
T-cell  ||| S:1074 E:1081 ||| JJ
response ||| S:1081 E:1089 ||| NN
.  ||| S:1089 E:1091 ||| .
Recently ||| S:1091 E:1099 ||| RB
,  ||| S:1099 E:1101 ||| ,
the  ||| S:1101 E:1105 ||| DT
concept  ||| S:1105 E:1113 ||| NN
that  ||| S:1113 E:1118 ||| IN
complement  ||| S:1118 E:1129 ||| JJ
activation  ||| S:1129 E:1140 ||| NN
is  ||| S:1140 E:1143 ||| VBZ
unfavorable  ||| S:1143 E:1155 ||| JJ
for  ||| S:1155 E:1159 ||| IN
tumor  ||| S:1159 E:1165 ||| NN
growth  ||| S:1165 E:1172 ||| NN
has  ||| S:1172 E:1176 ||| VBZ
been  ||| S:1176 E:1181 ||| VBN
drastically  ||| S:1181 E:1193 ||| RB
challenged  ||| S:1193 E:1204 ||| VBN
by  ||| S:1204 E:1207 ||| IN
evidence  ||| S:1207 E:1216 ||| NN
that  ||| S:1216 E:1221 ||| IN
points  ||| S:1221 E:1228 ||| NNS
to  ||| S:1228 E:1231 ||| TO
a  ||| S:1231 E:1233 ||| DT
novel  ||| S:1233 E:1239 ||| NN
immunomodulatory  ||| S:1239 E:1256 ||| NN
role  ||| S:1256 E:1261 ||| NN
of  ||| S:1261 E:1264 ||| IN
complement  ||| S:1264 E:1275 ||| NN
in  ||| S:1275 E:1278 ||| IN
the  ||| S:1278 E:1282 ||| DT
tumor  ||| S:1282 E:1288 ||| NN
microenvironment ||| S:1288 E:1304 ||| NN
.  ||| S:1304 E:1306 ||| .
Taken  ||| S:1306 E:1312 ||| VBN
together ||| S:1312 E:1320 ||| RB
,  ||| S:1320 E:1322 ||| ,
these  ||| S:1322 E:1328 ||| DT
findings  ||| S:1328 E:1337 ||| NNS
form  ||| S:1337 E:1342 ||| VBP
a  ||| S:1342 E:1344 ||| DT
new  ||| S:1344 E:1348 ||| JJ
conceptual  ||| S:1348 E:1359 ||| JJ
framework  ||| S:1359 E:1369 ||| NN
that  ||| S:1369 E:1374 ||| IN
integrates  ||| S:1374 E:1385 ||| JJ
innate  ||| S:1385 E:1392 ||| JJ
immunity  ||| S:1392 E:1401 ||| NN
to  ||| S:1401 E:1404 ||| TO
cancer  ||| S:1404 E:1411 ||| NN
development ||| S:1411 E:1422 ||| NN
.  ||| S:1422 E:1424 ||| .
Furthermore ||| S:1424 E:1435 ||| RB
,  ||| S:1435 E:1437 ||| ,
they  ||| S:1437 E:1442 ||| PRP
are  ||| S:1442 E:1446 ||| VBP
anticipated  ||| S:1446 E:1458 ||| VBN
to  ||| S:1458 E:1461 ||| TO
lead  ||| S:1461 E:1466 ||| VB
to  ||| S:1466 E:1469 ||| TO
the  ||| S:1469 E:1473 ||| DT
rational  ||| S:1473 E:1482 ||| JJ
design  ||| S:1482 E:1489 ||| NN
of  ||| S:1489 E:1492 ||| IN
strategies  ||| S:1492 E:1503 ||| NNS
that  ||| S:1503 E:1508 ||| WDT
will  ||| S:1508 E:1513 ||| MD
exploit  ||| S:1513 E:1521 ||| VB
innate  ||| S:1521 E:1528 ||| JJ
immune  ||| S:1528 E:1535 ||| JJ
systems ||| S:1535 E:1542 ||| NNS
,  ||| S:1542 E:1544 ||| ,
such  ||| S:1544 E:1549 ||| JJ
as  ||| S:1549 E:1552 ||| IN
complement ||| S:1552 E:1562 ||| NN
,  ||| S:1562 E:1564 ||| ,
in  ||| S:1564 E:1567 ||| IN
a  ||| S:1567 E:1569 ||| DT
patient-oriented ||| S:1569 E:1585 ||| JJ
,  ||| S:1585 E:1587 ||| ,
individualized  ||| S:1587 E:1602 ||| JJ
manner  ||| S:1602 E:1609 ||| NN
for  ||| S:1609 E:1613 ||| IN
effective  ||| S:1613 E:1623 ||| JJ
cancer  ||| S:1623 E:1630 ||| NN
immunotherapy ||| S:1630 E:1643 ||| NN
.  ||| S:1643 E:1645 ||| .
